Study type

Study topic

Disease /health condition

Study type

Non-interventional study

Scope of the study

Disease epidemiology

Data collection methods

Secondary use of data
Non-interventional study

Non-interventional study design

Cohort
Study drug and medical condition

Medical condition to be studied

Chronic obstructive pulmonary disease

Additional medical condition(s)

Exacerbations of chronic obstructive pulmonary disease, Cardiovascular events
Population studied

Short description of the study population

Patients with COPD and aged 45 years or older were identified within the ReS database from 2015 to 2018. Patients with at least one day of follow-up after the index date were included. Both newly diagnosed (defined as the absence of COPD criteria within the 24-month look-back period) and previously diagnosed patients with COPD were included.

Age groups

Adult and elderly population (≥18 years)
Adults (18 to < 65 years)
Adults (18 to < 46 years)
Adults (46 to < 65 years)
Elderly (≥ 65 years)
Adults (65 to < 75 years)
Adults (75 to < 85 years)
Adults (85 years and over)
Study design details

Study design

Observational retrospective longitudinal cohort study. Patients with COPD and aged 45 years or older were identified
between January 1st 2015 and December 31st 2018 and followed from index date to the first occurrence of a severe CV event/right censoring due to reaching 31/12/2019/loss to follow-up

Main study objective

The aim of this study was to evaluate the association between time periods following an exacerbation of COPD and the occurrence of a severe CV event compared to unexposed time periods (i.e., without an exacerbation), using data from the Italian National Health Service (SSN).

Setting

Italian inhabitants or beneficiaries of the SSN which is a unversal coverage health system.
Inhospital/local outpatient settings.
Overall observation period: 2013-2019.
Patients aged ≥45 were identified as having COPD by at least one of the following criteria: at least one hospitalization with a primary/secondary diagnosis of COPD in the hospital discharge forms (ICD-9CM codes: 491.x, 492.x, 496); disease waiver claims for COPD (057); at least 4 dispensations of drugs for obstructive airway diseases (ATC code: R03) within a same 12-month period. Patients with at least one day of follow-up after the index date were included.
Patients with Alpha-1-antitrypsin deficiency (ICD-9-CM code 273.4) and patients with asthma during the accrual period were excluded.

Summary results

Of 216,864 COPD patients, >55 % were male, mean age was 74 years, frequent comorbidities were
cardiovascular, metabolic and psychiatric.
During an average 34-month follow-up, 69,620 (32 %) patients had ≥1 exacerbation and 46,214 (21 %) experienced ≥1 cardiovascular event. During follow-up, 55,470 patients died; 4,661 were in-hospital cardiovascular-related deaths.
Among 10,269 patients experiencing cardiovascular events within 365 days post-exacerbation, the IR was 15.8 per 100 person-years (95 %CI 15.5–16.1).
Estimated hazard ratios (HR) for the cardiovascular event risk associated with periods post-exacerbation were highest within 7 days (HR: 34.3, 95 %CI: 33.1–35.6), especially for heart failure (HR 50.6; 95 %CI 48.6–52.7) and remained elevated throughout 365 days (HR 1.1, 95 %CI 1.02–1.13).